Plasticell receives EU funding as part of €3.7 million consortium

Parkinson´s, Huntington´s and Demyelination diseases to be tackeled

05-Nov-2018 - Plasticell Ltd, a developer of stem cell technologies and regenerative medicines, has announced that the Advanced Stem Cell Training Network (ASCTN), a European research consortium in which the company is a partner organisation, has successfully bid for over €3,700,000 in funding from the ...

Plasticell and GSK sign collaboration agreement

Contains production of hematopoietic cells from iPSCs

18-Oct-2017 - Plasticell, the biotechnology company specialising in stem cell screening and cell therapy development, has entered into a collaboration with GSK to use its combinatorial stem cell screening technology, CombiCult®, to optimise the directed differentiation of induced pluripotent stem cells (iPSCs) ...

Plasticell appoints Dr Aaron T. T. Chuang as Chief Scientific Officer

18-Jun-2015 - Plasticell has recruited Dr Aaron Chuang to its executive management team in the role of Chief Scientific Officer (CSO). Prior to this appointment, Dr Chuang served as Research Director at the Regenerative Medicine unit of GlaxoSmithKline (GSK), where he worked for over 18 years. As Plasticell’s ...

Plasticell wins £1.6 million funding

09-Feb-2015 - Plasticell has announced that Innovate UK has made a further investment in a therapeutic programme utilising CombiCult®, the high throughput stem cell technology designed to solve bottlenecks in regenerative medicine development. Innovate UK will provide a grant of approximately £1.3 million to a ...

Plasticell and EMD Millipore complete licensing deal to distribute fully defined, xeno-free mesenchymal stem cell differentiation media

16-Aug-2012 - Plasticell has licensed EMD Millipore to distribute a superior, single-application osteogenic medium discovered using the combinatorial screening system, CombiCult®.The osteogenic medium is serum- and xeno- free, more consistent and more potent than currently available formulations. Under the ...

Plasticell announces grant of fundamental CombiCult patents in USA and Japan

15-Feb-2012 - Plasticell announced that patents for its combinatorial cell culture platform technology, CombiCult™, have been granted in the USA and Japan. Patents covering CombiCult™ have now been issued in Europe, USA, Japan, Australia and Singapore.“Plasticell's proprietary technology breaks the major ...

Plasticell Spins Out Regenerative Drug Discovery Venture

New demerged business called ‘Progenitor Labs’

15-Apr-2011 - Plasticell Ltd has announced today that following its recent £3.5m financing, it has undergone a strategic re-structuring to enable the Company to focus on its award winning CombiCult™ technology for stem cell differentiation. Consequently, Plasticell Ltd has demerged its regenerative drug ...

Plasticell signs technology agreement with Sigma-Aldrich: Collaboration to produce novel turnkey solution for stem cell research

01-Dec-2010 - Plasticell has announced the signing of a collaboration agreement with Sigma-Aldrich, a leading provider of technologies and reagents to the life science research market. In the collaboration, Sigma-Aldrich will use its CompoZr® Zinc Finger Nuclease Technology to engineer various human stem cell ...

Plasticell signs collaboration with UCB

First in kind deal to partner small molecule drugs for stem cell research

10-Nov-2010 - Plasticel has announced signing of a collaboration agreement with UCB. Under the terms of the agreement, UCB will supply Plasticell with drug compound libraries with known biological targets. Plasticell will screen these using its award-winning CombiCult™ technology to discover new cell signaling ...

Latest Research Shows Proof of Concept in the Development of New Drugs to Regenerate Damaged Tissues and Organs

15-May-2009 - New research announced by Plasticell, a UK regenerative medicine biotech company, shows how it is possible to identify novel small molecule drugs which encourage the body to regenerate, potentially paving the way for the development of pills for repairing organs damaged by disease or ...